Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder

@article{Simpson2004SpotlightOA,
  title={Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder},
  author={D. Simpson and G. Plosker},
  journal={CNS Drugs},
  year={2004},
  volume={18},
  pages={397-401}
}
  • D. Simpson, G. Plosker
  • Published 2004
  • Medicine
  • CNS Drugs
  • AbstractAtomoxetine (Strattera™) is a selective noradrenaline (norepinephrine) reuptake inhibitor and nonstimulant that has shown greater efficacy than placebo in attention-deficit hyperactivity disorder (ADHD) in adults. In two large, well controlled, 10-week trials in adults with ADHD, improvements in ADHD symptoms, as assessed by investigator- and patient-rated scores, were greater with oral atomoxetine (60, 90 or 120 mg/day) than with placebo. Mean reductions in the total ADHD symptom score… CONTINUE READING
    Atomoxetine for attention deficits following traumatic brain injury: Results from a randomized controlled trial
    19

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 15 REFERENCES